Immunogenicity

TOT BIOPHARM Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020

Retrieved on: 
Tuesday, March 23, 2021

TOT BIOPHARM's core products including mAb drug TAB008 and ADC drug TAA013 have achieved key milestones.

Key Points: 
  • TOT BIOPHARM's core products including mAb drug TAB008 and ADC drug TAA013 have achieved key milestones.
  • The clinical results show that TAB008 has similar efficacy, safety, immunogenicity and pharmacokinetics profiles with the brand-name formulation of bevacizumab.
  • -- In 2020, the GMP compliance inspection of the production workshop for chemical drugs was completed, laying a foundation for the commercial production of chemical drugs.
  • commercial collaboration for drug candidates: At present, TOT BIOPHARM has multiple product pipelines such as biological drugs, ADC drugs and chemical drugs, which are stepping into the commercial stage with huge market potential.

Agilex Biolabs Showcases Advanced Immunoassay and Immunobiology Services at Bio-Europe Spring 2021

Retrieved on: 
Wednesday, March 17, 2021

ADELAIDE, AU, Mar 17, 2021 - (ACN Newswire) - Agilex Biolabs, Australia's largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.

Key Points: 
  • ADELAIDE, AU, Mar 17, 2021 - (ACN Newswire) - Agilex Biolabs, Australia's largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.
  • Sales Agilex Biolabs' Director Immunoassay said:
    "Our experienced team can develop or transfer a method for any biologic to support pre-clinical GLP or clinical studies.
  • Agilex Biolabs also features a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program.
  • We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.

Repertoire Immune Medicines Pre-publishes New Research Identifying Potential Mechanisms for Immune Escape of SARS-CoV-2 Variants to Support Novel Approaches for T Cell Based Therapeutic Development

Retrieved on: 
Wednesday, March 3, 2021

This research indicates how SARS-CoV-2 variants may avoid immune surveillance and informs the design of new T cell-based vaccines that can provide long term immunity.

Key Points: 
  • This research indicates how SARS-CoV-2 variants may avoid immune surveillance and informs the design of new T cell-based vaccines that can provide long term immunity.
  • The results also highlight the ability of Repertoires proprietary DECODE platform to identify T cells and the disease relevant epitopes that they engage, supporting the development of novel immune medicines.
  • Understanding T cell engagement at the precise epitope level should guide the development of novel therapeutic approaches beyond applications to SARS-CoV-2.
  • To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com and follow us on LinkedIn and Twitter .

Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy

Retrieved on: 
Wednesday, February 24, 2021

These findings underscore the promise of Selectas ImmTOR platform to address current limitations, notably immunogenicity, safety and durability, of gene therapy.

Key Points: 
  • These findings underscore the promise of Selectas ImmTOR platform to address current limitations, notably immunogenicity, safety and durability, of gene therapy.
  • The results in this publication continue to expand our knowledge of and validate the benefits of co-administering ImmTOR with AAV gene therapies, said Carsten Brunn, Ph.D., president and chief executive officer of Selecta.
  • We look forward to continuing to investigate the benefits of adding ImmTOR to gene therapy in clinical studies this year.
  • Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.

AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 17, 2021

LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10th Annual Global Healthcare Conference, taking place virtually on February 2226, 2021.

Key Points: 
  • LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10th Annual Global Healthcare Conference, taking place virtually on February 2226, 2021.
  • During a fireside chat, AC Immune CEO Prof. Andrea Pfeifer will discuss the Companys execution strategy to advance and accelerate its precision medicine approach to targeting neurodegenerative diseases.
  • Prof. Pfeifer will also highlight AC Immunes novel anti-phospho-Tau (pTau) vaccine candidate ACI-35.030, including recent interim Phase 1b/2a results that showed promising immunogenicity and safety in patients with early Alzheimers disease.
  • AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases.

COVAXX's COVID-19 Vaccine, UB-612, Induced Neutralizing Antibodies in 100% of Participants During Phase 1 Clinical Trial

Retrieved on: 
Monday, February 8, 2021

Dallas, Texas--(Newsfile Corp. - February 8, 2021) - COVAXX, a U.S. company developing UB-612, a multitope protein/synthetic peptide-based vaccine to fight COVID-19, today announced positive interim Phase 1 data from its open-label COVID-19 clinical trial conducted in Taiwan.

Key Points: 
  • Dallas, Texas--(Newsfile Corp. - February 8, 2021) - COVAXX, a U.S. company developing UB-612, a multitope protein/synthetic peptide-based vaccine to fight COVID-19, today announced positive interim Phase 1 data from its open-label COVID-19 clinical trial conducted in Taiwan.
  • This study which evaluated the safety, tolerability, and immunogenicity of UB-612, showed that the vaccine was generally well-tolerated and elicited robust antibody responses comparable to those seen in human convalescent sera.
  • To view the full announcement, including downloadable images, bios, and more, click here .
  • For more information on the COVAXX/UBI antibody test and the synthetic, peptide-based vaccine against COVID-19, visit www.covaxx.com and follow us on social media @covaxxvaccine.

Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001

Retrieved on: 
Monday, February 1, 2021

Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of tau, today announced results from its Phase 1 study of PNT001, a novel tau antibody that uniquely targets a toxic epitope known to drive neurodegenerative disease.

Key Points: 
  • Pinteon Therapeutics, a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of tau, today announced results from its Phase 1 study of PNT001, a novel tau antibody that uniquely targets a toxic epitope known to drive neurodegenerative disease.
  • PNT001 is a monoclonal antibody targeting an epitope on a highly neurotoxic conformation of the tau protein called cis-pT231 tau.
  • The Phase 1 study was designed to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of intravenously administered PNT001 in healthy adult volunteers.
  • Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease.

Advanced Antibodies, 2020 Report Profiles Key Companies Which are Highly Innovative and Primed for Growth in the Near Term - ResearchAndMarkets.com

Retrieved on: 
Friday, January 22, 2021

The "Advanced Antibodies, 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Advanced Antibodies, 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report profiles companies (excluding Tier 1 pharma/biopharma companies), which are highly innovative and primed for growth in the near term.
  • It has excluded companies, which have candidates in pre-clinical/phase 1 development, and is focused on companies, which would have a near term commercial realization.
  • Bispecific antibodies represent a highly promising class of therapeutics and were conceptualized more than 5 decades ago, but challenges associated with protein engineering, immunogenicity, stability, and manufacturing have dampened their commercialization.

Affinivax to Present at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 7, 2021

Affinivax, Inc. ("Affinivax"), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, today announced that Steven Brugger, president and CEO of Affinivax, will deliver a company presentation at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m.

Key Points: 
  • Affinivax, Inc. ("Affinivax"), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, today announced that Steven Brugger, president and CEO of Affinivax, will deliver a company presentation at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m.
  • The virtual presentation will provide an overview of the company, its proprietary MAPS platform, and pipeline of MAPS vaccines for infectious diseases.
  • ASP3772 was observed to be safe and highly immunogenic in a Phase 1 study in adults aged 18 to 64.
  • Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Childrens Hospital.

Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform

Retrieved on: 
Wednesday, January 6, 2021

This trial is being conducted in collaboration with Oregon Health & Science Universitys (OHSU) Vaccine and Gene Therapy Institutewith support from the Bill & Melinda Gates Foundation.

Key Points: 
  • This trial is being conducted in collaboration with Oregon Health & Science Universitys (OHSU) Vaccine and Gene Therapy Institutewith support from the Bill & Melinda Gates Foundation.
  • The randomized, placebo-controlled, Phase 1 clinical trial is evaluating the safety and immunogenicity (ability to induce an immune response) of VIR-1111.
  • Along with the many OHSU investigators who worked on this project over the years, we are very excited that this new vaccine platform is being evaluated in a clinical trial, Drs.
  • Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.